Kerri Ford

Sanofi, Bridgewater, NJ

Presentation(s):

• SP03K - Disease Severity and Outcomes Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic: Real-world US Experience with Sarilumab from the ACR RISE Registry

  Tuesday, August 24, 2021
  3:30 PM – 4:45 PM US Eastern Time